atazanavir has been researched along with rifampin in 5 studies
| Studies (atazanavir) | Trials (atazanavir) | Recent Studies (post-2010) (atazanavir) | Studies (rifampin) | Trials (rifampin) | Recent Studies (post-2010) (rifampin) |
|---|---|---|---|---|---|
| 75 | 1 | 37 | 20,468 | 1,499 | 6,552 |
| Protein | Taxonomy | atazanavir (IC50) | rifampin (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.949 | |
| Caspase-1 | Homo sapiens (human) | 8.319 | |
| Alpha-synuclein | Homo sapiens (human) | 7.1 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 0.03 | |
| DNA-directed RNA polymerase subunit beta | Mycobacterium tuberculosis H37Rv | 0.01 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acosta, EP; Agarwala, S; Alston-Smith, B; Bertz, R; Child, M; Gerber, JG; Haas, DW; Hosey, L; Kendall, MA; Koletar, SL; Zolopa, AR | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
2 review(s) available for atazanavir and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
3 other study(ies) available for atazanavir and rifampin
| Article | Year |
|---|---|
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Atazanavir Sulfate; Biotransformation; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Rifampin; Tuberculosis | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |